// App-Quantinova.ai

: COPD exacerbations in the phase 3 revefenacin clinical trial program

Researchers

Presenter

  • James F. Donohue

Principal Investigators

  • Sanjay Sethi

  • Craig N. Barnes

  • Edmund J. Moran

  • Srikanth Pendyala

  • Glenn Crater

  • Brett Haumann

Medical Centers

  • UNC School of Medicine, Chapel Hill, NC, United States of America

  • University at Buffalo, State University of New York, Buffalo, United States of America

  • Theravance Biopharma US, Inc., South San Francisco, United States of America

  • Theravance Biopharma UK, Limited, London, United Kingdom,

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Revefenacin

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Active Comparator

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved